Evolocumab Reduces LDL in Patients With Type 2 Diabetes and Hyperlipidemia
Treatment with evolocumab significantly reduced low-density lipoprotein cholesterol but had no notable impact on glycemic measures in Chinese patients with type 2 diabetes and dyslipidemia.